|| Checking for direct PDF access through Ovid
Two studies in hydrocephalic children and adolescents were performed to assess the penetration of linezolid into cerebrospinal fluid and its relation to meningeal inflammation.Each patient was administered intravenous linezolid 10 mg/kg every 12 hours for 3 days (study 1) or every 8 hours for 2 days (study 2). Pharmacokinetic indices (Cmax, Cmin, Tmax, AUC) were determined for plasma and ventricular fluid (VF) after the first and last doses.In study 1, after the last dose, the mean Cmax values for plasma and VF were 10.30 μg/mL (range, 3.95–16.6 μg/mL) and 7.54 μg/mL (range, 2.26–12.6 μg/mL), respectively; mean Cmin values were 1.32 μg/mL (range, 0.08–3.66 μg/mL) and 1.26 μg/mL (range, 0.19–2.58 μg/mL), respectively. The VF:plasma ratio based on last dose AUC0–12 was 0.98 μg h/mL (range, 0.64–1.22 μg h/mL). In study 2, after the last dose, the mean plasma and VF Cmax levels were 9.83 μg/mL (range, 3.19–16.5 μg/mL) and 5.84 μg/mL (range, 1.82–9.34 μg/mL), respectively; mean plasma and VF Cmin levels were 1.12 μg/mL (range, 0.10–3.39 μg/mL) and 1.94 μg/mL (range, 0.34–4.62 μg/mL), respectively. The VF:plasma ratio based on last dose AUC0–8 was 0.95 μg h/mL (range, 0.62–1.31 μg h/mL). Inflammation of the meninges did not seem to influence penetration of linezolid to the VF.Both studies showed that VF concentrations were variable. Further investigation of the role of linezolid in the treatment of CNS infection is needed.